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n 2013, the American Cancer Society estimated that 60 220 new cases of thyroid carcinoma would be diagnosed in the United States, and 1850 persons would die of the disease. The overall incidence of thyroid carcinoma has increased more rapidly than that of any other malignancy in recent years, especially in women, from 1.3 per 100 000 in 1935 to 16.3 per 100 000 in 2008.
1,2 Most thyroid carcinomas (95%) are derived from follicular epithelial cells and are mainly well differentiated, including papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC), with a minor fraction of poorly differentiated carcinomas (PDCs) and undifferentiated carcinomas (UDCs). 3 Only 3% of thyroid carcinomas are medullary carcinomas (MCs) derived from parafollicular C cells.
The diagnosis of thyroid carcinomas is straightforward in most cases. However, pathologists are not infrequently confronted with lesions exhibiting equivocal features that make the distinction of benign from malignant difficult. Although the diagnostic criteria for PTC and FTC are clearly outlined in textbooks, the application of the criteria is subjective and circumstantial. Interobservor or intraobservor disagreements in the diagnosis of follicular thyroid lesions are well documented, even among expert pathologists. [4] [5] [6] [7] In recent years, tremendous efforts in search of objective measures that differentiate benign from malignant lesions have been undertaken, mainly involving immunohistochemical markers and molecular markers, using somatic mutation, gene expression, and microRNA analyses. The immunohistochemical markers are the scope of this review. The objective of this article is to assess the diagnostic utility of the most commonly studied and published immunomarkers in the current literature in the field of thyroid pathology.
IMMUNOMARKERS USED IN THYROID-ORGAN
SPECIFIC DIFFERENTIATION Thyroid transcription factors (TTFs) TTF1, paired box gene 8 (PAX8), and TTF2 (FOXE1) are crucial for thyroid organogenesis and differentiation. [8] [9] [10] [11] [12] [13] [14] The transcription factors control the expression of thyroglobulin (TGB), thyroperoxidase (TPO), thyroid-stimulating hormone receptor, and thyroid iodine transporter. 15, 16 Immunohistochemically, they serve as organ-specific immunomarkers. Thyroglobulin is the primary synthetic product of the thyroid and the macromolecular precursor of thyroid hormones (T3 and T4), serving as a specific marker for thyroid follicular cell origin. [17] [18] [19] Thyroid Transcription Factor 1 Thyroid transcription factor 1, also named NKX2 homeobox 1 (NKX2.1), is a nuclear protein, approximately 38 kDa, composed of a single polypeptide of 371 amino acids belonging to the family of homeodomain transcription factors. Thyroid transcription factor 1 plays a crucial role in the organogenesis and differentiation of thyroid and lung. [9] [10] [11] In addition, TTF1 transcripts were detected in developing diencephalon, restricted to the hypothalamic area and to the infundibulum at the earliest stages of their differentiation, forming the posterior lobe of the pituitary, namely, the neurohypophysis.
Thyroid transcription factor 1 expression by immunohistochemical analysis was initially exclusively identified in thyroid and lung epithelial tissues, including normal, benign, and malignant tissues. 18, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] In routine practice, TTF1 became one of the most commonly used immunomarkers to identify thyroid or lung primary tumor in the setting of metastasis and to differentiate adenocarcinoma from squamous cell carcinoma in poorly differentiated nonsmall cell carcinomas of the lung in small biopsy or cytologic specimens. In recent years, TTF1-positive, nonpulmonary, nonthyroid carcinomas have been reported, including colorectal, ovarian, breast, endometrial, and endocervical adenocarcinomas. [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Comparing the 2 commercially available TTF1 monoclonal antibodies, SPT24 and 8G7G3/1, the rate of aberrant TTF1 expression in nonpulmonary, nonthyroid carcinomas is higher for SPT24, greater than 10% in colorectal adenocarcinomas as reported by some investigators. However, if using the 8G7G3/1 clone, the aberrant expression rate is low, less than 2% in general.
Normal thyroid follicular cells and parafollicular cells show diffuse expression of TTF1. In thyroid neoplasm, TTF1 expression was reported in nearly 100% of PTCs, FTCs, and follicular adenomas (FAs); in approximately 90% of PDCs and MCs; and in none to fewer than 25% of UDCs.*
Paired Box Gene 8
Paired box gene 8 is a member of the paired box (PAX) family of transcription factors that is expressed during organogenesis of the thyroid gland, müllerian tract, and kidney. [47] [48] [49] [50] [51] [52] Expression of PAX8 was mainly reported in thyroid and renal neoplasms and infrequently in bladder tumors, as well as müllerian-origin malignancies (including ovarian malignant neoplasms). 26, 46, [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] Few studies 53,54 also reported its expression in thymic and parathyroid neoplasms. Recently, PAX8 expression was documented in pancreatic neuroendocrine tumors.
66- 68 Tacha et al 54 reported that other cancers, including carcinomas of breast, lung, prostate, gastrointestinal tract, liver, mesothelioma, melanoma, and testicular tumors, lacked PAX8 expression; 14% (3 of 22) of pancreatic adenocarcinomas and 40% (2 of 5) of rhabdomyosarcomas were PAX8 positive.
In normal tissues, strong nuclear staining for PAX8 was observed in follicular cells of the thyroid; müllerian epithelial cells including endometrium, endocervix, and secretory cells of the fallopian tube; renal tubular epithelium; epithelial lining of the vas deferens; as well as islet cells of the pancreas. 54 Diffuse weak to moderate nuclear staining was observed in some cases of parathyroid tissue and nonneoplastic thymic epithelial cells. Urothelium and squamous mucosa were reported to have weak and patchy staining. Several studies investigated PAX8 expression in thyroid neoplasms, reporting a positive rate of nearly 100% in PTCs and FAs, 43, 46, 53, 54, 69 91% to 100% in FTCs, 46, 53, 54 75% to 100% in PDCs, 46, 53, 58 and 50% to 80% in UDCs. 46, 53, 54, 56, 58 Medullary carcinomas were reported to be PAX8 nonreactive with rare exceptions: positive in 75% (6 of 8, most 1þ) 46 and 41% (13 of 32) 54 of cases.
Thyroid Transcription Factor 2
Thyroid transcription factor 2, also named forkhead box E1 (FOXE1), was originally identified as a thyroid-specific, forkhead-domain-containing nuclear protein capable of recognizing and binding to a DNA sequence present in the promoters of both TGB and TPO, 2 genes expressed exclusively in thyroid follicular cells. 15, 70 Thyroid transcrip- tion factor 2 expression is restricted to the thyroid; anterior pituitary; epithelia of the oropharynx, trachea, and esophagus; exocrine cells of the seminiferous tubules of the testis; and epidermis and hair follicles. 12, [71] [72] [73] [74] [75] [76] [77] [78] Thyroid transcription factor 2 is 1 of 3 TTFs that play critical roles in thyroid organogenesis and differentiation. However, TTF2 seems to play a role in the development of the negative controller of thyroid-specific gene expression. 79, 80 Mutations in TTF2 (FOXE1) may be involved in human disorders characterized by congenital hypothyroidism, thyroid dysgenesis, and cleft palate. 81, 82 There are only few studies in literature investigating TTF2 expression by immunohistochemical analysis in human tumors and normal tissues. Nonaka et al 46 reported that TTF2 was expressed exclusively in normal thyroid follicular cells and a few C cells in thyroid C-cell hyperplasia and thyroid neoplasms, including 100% of cases of PTC (17 of 17), FA (18 of 18), FTC (16 of 16), and PDC (7 of 7); 75% (6 of 8) of cases of MC in a focal staining pattern; and only 7% (2 of 28, focal 1þ, 1%-25% of nuclei) of cases of UDC. All other neoplastic and nonneoplastic tissues showed no reactivity, including lung, esophagus, stomach, colon, pancreas, kidney, breast, ovary, prostate, urinary bladder, skin, testis, lymph node, and soft tissue. Matoso et al 83 studied 6 cases of spindle cell foci in thyroid glands by immunohistochemical analysis and found that 100% (6 of 6) of cases showed nuclear staining for TTF2. Increased expression of TTF2 by in situ hybridization was reported in epidermis and basal cell carcinomas. Zhang et al 36 documented the lack of expression of TTF2 by immunohistochemical evaluation in 212 cases of ovarian and endometrial malignancies to ascertain that the TTF1-positive tumors in their study were indeed not follicular cell in origin.
Although there are only few studies evaluating TTF2 expression in neoplastic and nonneoplastic tissues by immunohistochemistry, the data are appealing. Further study in a large series of cases is deemed necessary to assess the diagnostic utility of TTF2 in routine practice.
Thyroglobulin
Thyroglobulin, a thyroid hormone precursor, is a glycoprotein synthesized by thyrocytes, transported to the apical surface and secreted into the follicles, constituting the major component of colloid. Immunohistochemically, TGB expression is diffuse in 100% of normal thyroid follicular epithelial cells and 83% to 100% of FAs. 18, 43, 84 However, the staining pattern in lesions with Hürthle cell morphology was reported as weak or focal. In primary thyroid carcinomas, the expression of TGB, both at the messenger RNA and protein level, showed a certain degree of correlation with tumor differentiation. Studies 18, 43, [84] [85] [86] [87] [88] have reported 100% expression of TGB in PTC, 75% to 96% in FTC, 57% to 92% in PDC, and near lack of expression in UDC and MC. Metastatic thyroid carcinomas were reported as showing staining patterns similar to those of the primary tumors. 18, 89 In nonthyroid tissues and tumors, including parathyroid gland, lung, stomach, pancreas, ovary, kidney, colon, salivary glands, prostate, breast, and glomus body, TGB expression was lacking. 43, [89] [90] [91] In our previous study, 92 TGB expression was demonstrated in 14 of 14 (100%) cases of normal thyroid tissue, 45 of 45 (100%) cases of PTC, 36 of 36 (100%) cases of FTC, and 0 of 10 (0%) cases of MC.
IMMUNOMARKERS USED IN THE DIFFERENTIAL DIAGNOSIS OF THYROID NEOPLASMS
The histomorphologic diagnosis of thyroid neoplasm remains the cornerstone in the classification of thyroid follicular lesions. However, for those tumors that are poorly differentiated or undifferentiated, not follicular derived, and exhibit equivocal histomorphologic features, the application of immunohistochemical biomarkers may play an active or complementary role in their accurate classification. [93] [94] [95] [96] [97] [98] [99] Among the variety of biomarkers reported in the literature, Hector Battifora mesothelial-1 (HBME-1), galectin-3 (GAL-3), cytokeratin 19 (CK19), Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain, 1 (CIT-ED1), and TPO are most promising. However, there is no single marker sensitive enough to provide a definitive malignant diagnosis. Therefore, different panels of combined immunomarkers were proposed by many investigators. 98, [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] The combination of HBME-1, GAL-3, and CK19 was by far the most common panel evaluated by investigators, and their diffuse expression has not been reported in benign lesions. Other markers, such as antibodies against proteins involved in cell proliferation and in the regulation of cell cycle, as well as oncogene proteins, are also being studied and documented in the literature. Recently, we found a distinct membranous staining pattern for trophoblastic cell surface antigen 2 (TROP2), a 35-kDa type 1 transmembranous glycoprotein, in PTCs; in contrast, follicular neoplasms (FAs and FTCs) were nonreactive or showed only rare focal, weak cytoplasmic staining. We propose that TROP2 is a potential novel immunomarker for the identification of PTC that can be used in a panel to increase diagnostic accuracy when encountering a difficult follicular cell-derived lesion.
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Hector Battifora Mesothelial-1
Hector Battifora mesothelial-1 is an unelucidated membrane antigen found in the microvilli of mesothelial cells, normal tracheal epithelium, and adenocarcinoma of the lung, pancreas, and breast. In the past decade, several studies have investigated HBME-1 expression in benign and malignant thyroid tissues; the published studies are reviewed and summarized in Table 1 . In normal thyroid tissue, there was virtually no expression of HBME-1. 104, 108, [114] [115] [116] Overexpression of HBME-1 was demonstrated in malignant thyroid neoplasms, especially PTCs, with the exception of Hürthle cell carcinomas. Several investigators 104, 108, [114] [115] [116] [117] [118] [119] have reported a reduced or lack of expression for HBME-1 in Hürthle cell carcinomas or thyroid neoplasms with Hürthle cell features. Studies suggested that overexpression of HBME-1 in a thyroid nodule was an indicator of malignancy, especially true for PTC. The overall sensitivity of HBME-1 was 78.8% for thyroid malignancy, 87.3% for PTC, and 65.2% for FTC. The specificity was 82.1%.
† Expression of HBME-1 was also noted in benign thyroid lesions such as FA, nodular goiter, and lymphocytic thyroiditis (LTis), usually in a focal staining fashion, with a reported overall positive rate of 26%, 12%, and 19%, respectively.
‡ Hyaline trabecular tumors were reported to lack HBME-1 expression, suggesting its discriminating role in the distinction between hyaline trabecular tumor and PTC; however, Lenggenhager et al 119 recently reported that 37.5% (3 of 8) of cases of hyaline trabecular tumor showed patchy but strong membranous and/or cytoplasmic reactivity to HBME-1. Many investigators proposed using a panel of immunomarkers, most commonly a combination of HBME-1, CK19, and GAL-3, to increase the discriminating power between benign and malignant neoplasms when a histologically equivocal lesion is encountered.
Cytokeratin 19
Cytokeratin 19 is a low-molecular-weight cytokeratin found in a variety of simple or glandular epithelia, both normal and their neoplastic counterparts. In the thyroid gland, normal follicular epithelium usually has shown no detectable CK19 expression 110, 115, 129 ; however, few re- ; therefore, positive CK19 staining lacks specificity for PTC or malignancy. Table 2 summarizes the data from studies of CK19 expression in various thyroid lesions. The overall sensitivity of CK19 was 79.3% for malignancy, 82.2% for PTC, and 44.3% for FTC. The specificity was 63.1%. Overexpression of CK19 is a good indicator for PTC; however, the sensitivity for follicular carcinoma is low. There are high rates of reactivity in benign thyroid lesions, especially in LTis. 114, 115 Compared with the diffuse, strong reactivity in PTC, most studies indicated focal reactivity in benign lesions. Cytokeratin 19 may have added value as part of a panel of immunomarkers in the diagnosis of PTC.
Galectin-3
Galectin-3 is a member of a family of b-galactosidebinding animal lectins shown to be involved in tumor progression and metastasis. Both nuclear and cytoplasmic expression of GAL-3 has been demonstrated in a variety of tissues and cells. Study of mouse 3T3 fibroblasts revealed the presence of both phosphorylated and nonphosphorylated GAL-3; the former resides in both nucleus and cytoplasm; the latter, exclusively in the nucleus. Cell proliferation is associated with an increased level of both forms, while alterations in nuclear versus cytoplasmic GAL-3 localization have been shown to be associated with neoplastic progression.
136,137 Galectin-3 plays an important role in cell-cell/cell-matrix adhesion, cell growth, neoplastic transformation/spread, cell cycle regulation/apoptosis, and cell repair processes. In recent years, overexpression of GAL-3 has been reported in various human carcinomas, most noticeably in well-differentiated follicular-derived thyroid carcinomas. Many studies ¶ investigated GAL-3 expression in cytologic and histologic specimens of thyroid nodular lesions; these are summarized in Table 3 . Galectin-3 has been found to be useful in differentiating malignant thyroid lesions (such as PTC and the follicular variant of PTC) from benign lesions. The overall sensitivity of GAL-3 was 84.6% for malignancy, 87.5% for PTC, and 72.6% for FTC. The specificity was 83.6%. In general, GAL-3 expression in benign lesions is often focal, and in contrast, is diffuse in malignant lesions.
Trophoblastic Cell Surface Antigen 2
Trophoblastic cell surface antigen 2, also known as tumorassociated calcium signal transducer 2 (TAC-STD2), is a transmembrane glycoprotein associated with tumor development and progression in a variety of epithelial carcinomas including ovarian, colorectal, pancreatic, gastric, pulmonary, endometrioid endometrial, and oral cavity squamous cell carcinomas. [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] In normal tissues, TROP2 expression was reported as low or lacking. Many studies [158] [159] [160] [161] [162] [163] have demonstrated that TROP2 overexpression is associated with tumor aggressiveness and poor prognosis.
Immunohistochemical evaluation of TROP2 expression in thyroid tumors has not been well studied. Recently, we (50) 8/52 (15) atypia showed lack of TROP2 expression. The staining results are summarized in Table 5 . The normal thyroid tissue on TMA revealed weak cytoplasmic staining; no membranous staining pattern was identified. The 10 surgical cases each of nodular hyperplasia and chronic LTis showed no TROP2 expression, except rare weak to moderate membranous staining in the lining cells of a degenerative cyst in 1 of the 10 cases of chronic LTis, as illustrated in Figure 1 , E and F. Our data suggest that TROP2 is a potential novel immunomarker for identification of both classic and follicular variants of PTC. Based on our study, TROP2 appears to be a more specific marker than the 3 traditional markers (CK19, HBME-1, and GAL-3); however, additional studies in a large number of difficult cases from multiple institutions are warranted to substantiate the current findings.
Thyroperoxidase
Thyroperoxidase is a thyroid-specific enzyme reflecting normal thyroid function. Thyroperoxidase expression is demonstrated in normal thyroid follicular epithelial cells, usually in diffuse fashion. 103, 164 During thyroid cell dedifferentiation, the expression of TPO is lost. Therefore, lack of TPO expression is regarded as a marker of malignancy. Several studies 103, 120, [164] [165] [166] [167] [168] [169] investigated the diagnostic utility of TPO in thyroid lesions, yielding a sensitivity of 90% for PTC and 76% for FTC and a specificity of 88%. Table 6 summarizes the data from reported studies of TPO expression in thyroid lesions. The earlier studies produced more promising results than recent ones. Thyroperoxidase appears highly sensitive for PTC but borderline to poorly sensitive for FTC. The staining patterns of FTC and FA showed a certain degree of overlapping without meaningful discriminatory value. A couple of recent studies 103 ,129 used a combination of TPO and GAL-3 to improve diagnostic accuracy. They yielded a sensitivity of 96% to 98% for PTC and 44% to 67% for FTC, proposing that the application of TPO immunostain in combination with other biomarkers is useful, and with added value in the diagnosis of PTC.
OTHER CELL ADHESION MOLECULES, CELL CYCLE
REGULATORY PROTEINS, AND ONCOGENES E-cadherin, a calcium-dependent transmembrane cell adhesion molecule, is required for normal epithelial function. Down-regulation of E-cadherin expression has been observed in various carcinomas and is usually associated with an advanced stage and progression. In normal and benign thyroid lesions, high expression of Ecadherin was demonstrated and restricted to thyrocytes. [170] [171] [172] In thyroid carcinomas, E-cadherin expression was reduced in PDC, lost in UDC, and preserved in most minimally invasive carcinomas. [170] [171] [172] [173] [174] [175] These studies suggest that loss of E-cadherin expression is the crucial event in dedifferentiation, progression, and metastatic spread of thyroid carcinomas.
Fibronectins (FNs), extracellular matrix proteins produced by fibroblasts, are involved in cell adhesion, migration, and tumor progression. Oncofetal FNs, isoforms of FN, are highly expressed in fetal and neoplastic tissues, especially PTCs. [176] [177] [178] [179] [180] Prasad et al 108 Cluster of differentiation (CD) 44v6 is the isoform of CD44, a cell surface membrane glycoprotein that plays a role in the regulation of cell-cell and cell-matrix interactions as well as cell migration. 181 Expression of CD44v6 has been reported in several carcinomas. [182] [183] [184] [185] Few studies investigating CD44v6 expression in thyroid lesions found overexpression of CD44v6 in well-differentiated PTCs and FTCs, suggesting the potential utility of CD44v6 in combination with GAL-3 in distinguishing benign from malignant thyroid neoplasms. [186] [187] [188] [189] [190] [191] However, CD44v6 expression was also demonstrated in benign lesions and poorly differentiated or undifferentiated thyroid carcinomas at a lower rate of expression. Cyclin-dependent kinase inhibitor 1B (p27 Kip1 ), a nuclear cyclin-dependent kinase inhibitor, plays a major role in controlling progression from the G1 to the S phase of the cell cycle. The loss of regulatory control of the cell cycle, leading to unrestrained cell proliferation, is the hallmark of cancers. Down-regulation of p27
Kip1 has been shown to correlate with histologic loss of differentiation or high-grade morphology in various human carcinomas [192] [193] [194] [195] [196] and is emerging as an important prognostic factor. Studies 197, 198 revealed strong nuclear reactivity in normal thyrocytes. In thyroid neoplasms, p27
Kip1 expression was significantly higher in benign lesions than malignant thyroid neoplasms, suggesting the potential utility of p27
Kip1 in the differentiation of benign from malignant follicular lesions. [197] [198] [199] [200] [201] Cyclin D1, a member of the family of cyclins, is a 36-kDa nuclear protein that functions as the regulatory subunit of cyclin-dependent kinases (CDK4 and CDK6) and controls the progression of the G1/S phases of the cell cycle. 202 Deregulation of cyclin expression results in the loss of control of normal cell growth and oncogenesis. Overexpression of cyclin D1 has been demonstrated in various human cancers, including thyroid carcinomas. 201, [203] [204] [205] [206] [207] [208] [209] Normal thyrocytes are immunohistochemically negative for cyclin D1. Studies have been conducted to investigate the expression of cyclin D1 in thyroid neoplasms. Melck et al 210 evaluated the expression of cell cycle regulators, including cyclin D1, in TMAs of 100 benign and 105 malignant thyroid lesions. They demonstrated overexpression of cyclin D1 in 87.1% of malignant and 45.7% of benign thyroid lesions; similar findings were reported by Seybt et al 211 and Park et al. 102 Wang et al 212 investigated cyclin D1 expression in 34 conventional PTCs, 10 minimally invasive It has been well demonstrated that cyclin D1 is overexpressed in malignant thyroid lesions compared to benign lesions; however, the staining patterns showed heterogeneity, which limits its utility as a diagnostic marker.
b-catenin, a 92-kDa multifunctional protein, plays an important role in cell adhesion and signal transduction and serves as a downstream effector in the Wnt signaling pathway. 214 In normal resting cells, b-catenin forms cytoplasmic/membranous-bound complexes with E-cadherin. Upon activation, b-catenin translocates to the nucleus, promoting tumor growth through activation of the Wnt signaling pathway. 93, [215] [216] [217] Normal thyroid follicular cells display a strong membranous immunoreactivity for bcatenin. 218, 219 Studies were conducted to investigate the expression and the pattern of expression of b-catenin in various thyroid tumors. Garcia-Rostan et al 218 PTC (33) 23 (70) 22 (67) 33 (100) 33 (100) AFN (11) 0 (0) 2 (18) 9 (82) 8 (73) ANFNA (17) 0 (0) 3 (18) 7 (41) 6 (35) Abbreviations: AFN, atypical follicular neoplasm; ANFNA, adenomatoid nodule with focal nuclear atypia; CK19, cytokeratin 19; GAL-3, galectin-3; HBME-1, Hector Battifora mesothelial-1; n, number of cases; PTC, papillary thyroid carcinoma. p53 is a tumor suppressor gene product that plays an important role in normal cell growth. Mutations of the TP53 gene lead to accumulation of p53, which can be detected by immunohistochemistry. p53 expression has been reported in various tumors, mainly in UDCs and PDCs and rarely in well-differentiated carcinomas as well as MCs in thyroid neoplasms. [220] [221] [222] [223] [224] [225] [226] BRAF Mutation-Specific Antibody
The BRAF (the B-isoform of RAF kinase) oncogene is mutated in several types of tumors, such as colorectal adenocarcinoma, PTC, glioma, gastrointestinal adenocarcinoma, melanoma, and pulmonary adenocarcinoma. 227 The most common mutation in BRAF is due to a T to A switch at position 1796, which results in an alteration from valine to glutamate at the V600E. The BRAF V600E point mutation has been reported in approximately 50% of PTCs, with a higher frequency (approximately 70%) in tall cell variant and oncocytic variant of PTC and a much lower frequency (approximately 20%) in follicular variant of PTC. 228 The BRAF V600E mutation is generally negative in benign follicular lesions, normal thyroid tissue, medullary carcinoma, and follicular carcinoma. A recent meta-analysis of 5655 patients suggested PTC with the BRAF mutation is associated with a higher risk of recurrent, persistent disease, lymph node metastasis, and extrathyroidal extension. 229 Many molecular techniques have been used to detect the BRAF V600E point mutation, including single-strand conformation polymorphism, mutation-specific polymerase chain reaction, direct gene sequencing, and colorimetric mutation analysis. These methods tend to be expensive, time-consuming, labor-intensive, and difficult to validate and implement in some clinical settings.
Recently, 2 mutation-specific antibodies against BRAF V600E have become commercially available; one is VE1 clone (Spring Bioscience, Pleasanton, California) and the other is anti-B-Raf mouse monoclonal antibody (New East Bioscience, Malvern, Pennsylvania). Most studies used VE1 clone, and only rare studies used anti-B-Raf mouse monoclonal antibody. 227, 228, [230] [231] [232] [233] In general, BRAF mutation-specific antibody has been shown to be useful in detection of the BRAF V600 mutation, with a sensitivity and specificity of more than 95% when compared to other molecular methods. 227, 228, [230] [231] [232] [233] In fact, some studies 228, 231 suggested that anti-BRAF mutation-specific antibody may be more sensitive than molecular testing in detecting the BRAF mutation. Data from selected studies of BRAF mutation-specific antibodies to detect the BRAF V600E mutation in PTCs, with the correlating molecular testing results, are summarized in Table 7 . An example of the BRAF mutation in a papillary thyroid microcarcinoma, detected by immunohistochemistry using the VE1 clone, is shown in Figure 2 , A through D.
CONCLUSIONS Cytomorphology or histomorphology remains the cornerstone for the diagnosis of thyroid lesions. However, not infrequently, we encountered cases with equivocal morphology that posed a great challenge in reaching an accurate diagnosis. Ancillary studies, including somatic mutation testing, messenger RNA gene expression platforms, protein immunohistochemistry, and microRNA panels, are becoming increasingly important. Immunohistochemistry by far is the most commonly used method to complement morphologic assessment. By reviewing the published data in the current literature, we have determined that there is no individual biomarker having sufficient sensitivity or speci- ficity to distinguish benign from malignant lesions. However, HBME-1 is often strongly and diffusely expressed in PTC; it can be used as a marker (in a panel) to aid in the PTC diagnosis. Galectin-3 (in a panel) can be useful in differentiating malignant from benign thyroid lesions; CK19 has low sensitivity and specificity. A panel of immunomarkers, as proposed by many investigators, is recommended when working on challenging thyroid follicular-derived lesions to improve diagnostic accuracy. The most commonly proposed panel is GAL-3, HBME-1, and CK19. We also recommend including TROP2 in the diagnostic panel. Other panels, such as the combination of 2 of the 3 markers or the addition of FN-1 or CITED-1, are also proposed. The application of a panel of immunomarkers improves the differential power of individual markers and aids in the accurate classification of challenging thyroid follicular-derived lesions. 
